{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:43:45Z","timestamp":1767681825625,"version":"3.48.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      <jats:italic>N-myristoylation<\/jats:italic>\n                      is a crucial lipid modification that governs protein localization, intracellular trafficking, and function in eukaryotic cells. The enzyme\n                      <jats:italic>N-myristoyltransferase<\/jats:italic>\n                      (NMT), which catalyzes this modification, has emerged as an attractive drug target for parasitic diseases. In this study, we performed a comprehensive biochemical and antiparasitic evaluation of\n                      <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                      NMT (TcNMT), utilizing novel \u201c\n                      <jats:italic>in silico<\/jats:italic>\n                      \u2013identified inhibitors\u201d to assess its potential as a therapeutic agent for Chagas disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Recombinant TcNMT was cloned, expressed, and purified for enzymatic characterization. Catalytic activity and substrate affinity were evaluated using a fluorescence-based assay. Four in-silico-selected NMT inhibitors were screened for (i) enzyme inhibition, (ii) cytotoxicity in human cardiomyocytes, and (iii) antiparasitic activity in\n                      <jats:italic>T. cruzi<\/jats:italic>\n                      \u2013infected cardiomyocytes. QUINE and the reference inhibitor DDD85646 were further characterized by calculating selectivity indices. Proteomic profiling of myristoylated proteins was conducted in amastigotes and trypomastigotes following treatment with DDD85646 to identify pathway-level effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All recombinant TcNMT preparations were catalytically active and displayed high affinity for peptide substrates. Among the screened compounds, QUINE showed moderate antiparasitic efficacy but very low cytotoxicity, yielding a high selectivity index (SI = 28.11). In contrast, DDD85646 exhibited greater antiparasitic potency but substantially higher host-cell toxicity (SI = 4.67). Proteomic analysis of DDD85646-treated parasites revealed downregulation of myristoylated proteins in both life stages, including ARF GTPases and enzymes associated with vesicular trafficking and lipid metabolism. Host cell proteomes remained largely unchanged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Biochemical characterization and phenotypic testing support TcNMT as a viable therapeutic target for Chagas disease. QUINE demonstrates the most favorable pharmacological profile, combining antiparasitic activity with excellent selectivity and low host toxicity, making it a strong lead candidate for future drug optimization. Proteomics data indicate that NMT inhibition disrupts critical pathways required for parasite viability yet spares host cellular machinery, reinforcing the mechanistic selectivity of TcNMT targeting. Further studies are warranted to improve potency and evaluate in vivo efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2025.1666768","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:41:09Z","timestamp":1767681669000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Trypanosoma cruzi N-myristoyltransferase as a drug target for Chagas disease through in silico discovery and biochemical evaluation"],"prefix":"10.3389","volume":"12","author":[{"given":"Diana","family":"Gonz\u00e1lez Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Talevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas N.","family":"Alberca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frida","family":"Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Da Silva Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila S. G.","family":"Farani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor C.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.exppara.2019.05.007","article-title":"Exploring protein myristoylation in Toxoplasma gondii","volume":"203","author":"Alonso","year":"2019","journal-title":"Exp. Parasitol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1074\/mcp.TIR119.001906","article-title":"A compact quadrupole-orbitrap mass spectrometer with FAIMS interface improves proteome coverage in short LC gradients","volume":"19","author":"Bekker-Jensen","year":"2020","journal-title":"Mol. Cell Proteomics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1056\/NEJMct1014204","article-title":"Antitrypanosomal therapy for chronic chagas' disease","volume":"364","author":"Bern","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B4","first-page":"93","article-title":"Growth and differentiation in trypanosoma cruzi. I. origin of metacyclic trypanosomes in liquid media","volume":"6","author":"Camargo","year":"1964","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"B5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.yjmcc.2005.03.003","article-title":"Novel cell lines derived from adult human ventricular cardiomyocytes","volume":"39","author":"Davidson","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"B6","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/vaccines12080870","article-title":"Treatments and the perspectives of developing a vaccine for chagas disease","volume":"12","author":"Farani","year":"2024","journal-title":"Vaccines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nature08893","article-title":"N-myristoyltransferase inhibitors as new leads to treat sleeping sickness","volume":"464","author":"Frearson","year":"2010","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"fny180","DOI":"10.1093\/femsle\/fny180","article-title":"Characterisation and pure culture of putative health-associated oral bacterium BU063 (tannerella sp. HOT-286) reveals presence of a potentially novel glycosylated S-layer","volume":"365","author":"Frey","year":"2018","journal-title":"FEMS Microbiol. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/emboj\/18.8.2057","article-title":"Flagellar protein localization mediated by a calcium-myristoyl\/palmitoyl switch mechanism","volume":"18","author":"Godsel","year":"1999","journal-title":"Embo J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ab.2011.10.013","article-title":"A fluorescence-based assay for N-myristoyltransferase activity","volume":"421","author":"Goncalves","year":"2012","journal-title":"Anal. Biochem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0004540","DOI":"10.1371\/journal.pntd.0004540","article-title":"Validation of N-myristoyltransferase as potential chemotherapeutic target in mammal-dwelling stages of Trypanosoma cruzi","volume":"10","author":"Herrera","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with alphafold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2500056","DOI":"10.1080\/19490976.2025.2500056","article-title":"Engineered bacteria as an orally administered anti-viral treatment and immunization system","volume":"17","author":"Kamble","year":"2025","journal-title":"Gut Microbes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"D1091","DOI":"10.1093\/nar\/gkt1068","article-title":"DrugBank 4.0: shedding new light on drug metabolism","volume":"42","author":"Law","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7206","DOI":"10.1074\/jbc.M211391200","article-title":"Myristoyl-CoA:protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites","volume":"278","author":"Price","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/s0140-6736(10)60061-x","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.idc.2012.03.002","article-title":"American trypanosomiasis (chagas disease)","volume":"26","author":"Rassi","year":"2012","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/b978-0-12-801029-7.00029-0","article-title":"Clinical phases and forms of chagas disease","author":"Rassi","year":"2017","journal-title":"Am. Trypanosomiasis Chagas Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"31078","DOI":"10.1038\/srep31078","article-title":"The N-myristoylome of Trypanosoma cruzi","volume":"6","author":"Roberts","year":"2016","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/bj20131033","article-title":"Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase","volume":"459","author":"Roberts","year":"2014","journal-title":"Biochem. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.1016\/s0021-9258(18)92882-6","article-title":"Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase","volume":"266","author":"Rudnick","year":"1991","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","article-title":"CellProfiler 4: improvements in speed, utility and usability","volume":"22","author":"Stirling","year":"2021","journal-title":"BMC Bioinforma."},{"key":"B23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1021\/ci600426e","article-title":"Evaluating virtual screening methods: good and bad metrics for the \u201cearly recognition\u201d problem","volume":"47","author":"Truchon","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1021\/jm050529o","article-title":"Scaffold hopping through virtual screening using 2D and 3D similarity descriptors: ranking, voting, and consensus scoring","volume":"49","author":"Zhang","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1666768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:41:14Z","timestamp":1767681674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1666768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":26,"alternative-id":["10.3389\/fmolb.2025.1666768"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1666768","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1666768"}}